PuraPharm Corporation Limited Stock price

Equities

1498

KYG7306Y1044

Pharmaceuticals

Delayed Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.83 HKD +2.47% Intraday chart for PuraPharm Corporation Limited +6.41% -7.78%
Sales 2021 660M 84.28M Sales 2022 448M 57.26M Capitalization 506M 64.62M
Net income 2021 -122M -15.59M Net income 2022 -120M -15.33M EV / Sales 2021 1.14 x
Net Debt 2021 436M 55.7M Net Debt 2022 427M 54.6M EV / Sales 2022 2.08 x
P/E ratio 2021
-2.62 x
P/E ratio 2022
-4.2 x
Employees 30
Yield 2021 *
-
Yield 2022
-
Free-Float 47.06%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.47%
1 week+6.41%
Current month+1.22%
1 month-2.35%
3 months-7.78%
6 months-29.66%
Current year-7.78%
More quotes
1 week
0.80
Extreme 0.8
0.86
1 month
0.75
Extreme 0.75
0.90
Current year
0.74
Extreme 0.74
0.95
1 year
0.74
Extreme 0.74
1.26
3 years
0.66
Extreme 0.66
2.00
5 years
0.56
Extreme 0.56
2.74
10 years
0.56
Extreme 0.56
5.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 98-05-04
Sales & Marketing - -
Human Resources Officer - -
Members of the board TitleAgeSince
Director/Board Member 65 15-06-11
Director/Board Member 70 15-06-11
Chief Executive Officer 63 98-05-04
More insiders
Date Price Change Volume
24-03-28 0.83 +2.47% 100,000
24-03-27 0.81 0.00% 55,000
24-03-26 0.81 -3.57% 11,500
24-03-25 0.84 +7.69% 98,500
24-03-22 0.78 0.00% 0

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. The Company operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock PuraPharm Corporation Limited - Hong Kong S.E.